Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Publication year range
1.
Clin Lymphoma Myeloma Leuk ; 24(1): 55-63, 2024 01.
Article in English | MEDLINE | ID: mdl-37838502

ABSTRACT

BACKGROUND: Daratumumab, lenalidomide and dexamethasone (DRd) and bortezomib, lenalidomide and dexamethasone (VRd) are preferred regimens for transplant ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). Both DRd and VRd demonstrated superior efficacy versus Rd in the MAIA and SWOG S0777 trials, respectively, but there is no head-to-head (H2H) clinical trial comparing their efficacy. Differing populations in the MAIA and S0777 trials make an unadjusted comparison of outcomes challenging and biased. The current TAURUS study is the first real-world H2H study comparing progression-free survival (PFS) among TIE NDMM patients treated with DRd or VRd as first-line (1L) in similar clinical settings. MATERIALS AND METHODS: A multicenter chart review study was conducted at nine sites across the United States. All TIE patients treated with DRd and a randomly selected population of VRd patients were included. TIE NDMM patients aged ≥65 were included if they initiated 1L DRd/VRd between January 2019 and September 2021. PFS was defined as the time from DRd/VRd initiation until disease progression or death. A doubly-robust multivariable Cox regression model combined with inverse probability of treatment weighting (IPTW) methodology was used to compare PFS between cohorts. RESULTS: Weighted cohorts comprised 91 DRd and 87 VRd patients. Thirteen DRd and 24 VRd patients experienced progression/death. Patients treated with DRd had a lower risk of progression/death versus VRd (adjusted hazard ratio: 0.35, 95% confidence interval: [0.17; 0.73]). CONCLUSION: DRd is associated with a significantly lower risk of disease progression or death compared to VRd as 1L treatment for TIE NDMM patients.


Subject(s)
Antibodies, Monoclonal , Multiple Myeloma , Humans , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bortezomib/therapeutic use , Dexamethasone/therapeutic use , Disease Progression , Lenalidomide/therapeutic use , Multiple Myeloma/therapy , Progression-Free Survival , Aged , Clinical Trials as Topic
2.
Rev. Inst. Med. Trop. Säo Paulo ; 35(6): 585-7, nov.-dez. 1993. ilus
Article in Portuguese | LILACS | ID: lil-140128

ABSTRACT

Os autores relatam caso clinico de paciente com esquistossomose mansonica, tratado com oxamniquine oral em dose unica de 15mg/Kg, que apresenta como efeito colateral um bloqueio atrio-ventricular incompleto tipo Mobitz I, com parada sinusal e escape ventricular. Concluem que, apesar de a oxamniquine ser eficaz e segura, pode ser determinante de cardiotoxicidade.


Subject(s)
Humans , Male , Adolescent , Arrhythmias, Cardiac/etiology , Oxamniquine/therapeutic use , Schistosomiasis mansoni/therapy , Oxamniquine/adverse effects
3.
Semina ; 14(2): 58-60, jun. 1993.
Article in Portuguese | LILACS | ID: lil-261295

ABSTRACT

Neste trabalho o autor apresenta e discute algumas propostas de atividades de monitoria em semiologia médica, salientando a importância da participaçäo estudantil na potencializaçäo da aprendizagem e na evoluçäo do ensino médico. É enfatizado um sistema dinâmico de instruçäo-aprendizagem, supervisionado por docente orientador, que objetiva uma formaçäo global do aluno, através de estímulo ao aprendizado de semiologia médica


Subject(s)
Students, Medical , Faculty, Medical , Medical History Taking , Diagnosis , Education, Medical
SELECTION OF CITATIONS
SEARCH DETAIL